Serina Therapeutics has entered into definitive agreements for a private placement that could provide up to $30 million to support the advancement of its clinical trial evaluating SER-252 (POZ-apomorphine) as a treatment for people with advanced Parkinson’s disease. The global Phase 1b trial (NCT07422675) is evaluating the…
News
Treatment with pirepemat, an oral medication in the pipeline at Irlab Therapeutics AB, may help reduce the risk of falls in people with Parkinson’s disease when reaching its optimal blood concentration, according to newly shared data from a clinical trial in Europe. “Topline results showed a markedly reduced…
Scientists have developed an experimental gene therapy with the potential to treat early-onset Parkinson’s disease associated with PRKN gene mutations, according to a new preclinical study. Delivery of the gene therapy carrying a functional version of the PRKN gene into the brains of two mouse…
Biological changes associated with Parkinson’s disease, including newly identified changes in a signaling network linked to neuroinflammation, or brain inflammation, may begin up to 12 years before diagnosis. That’s according to data from a proof-of-concept study of Grifols’ Chronos-PD research initiative, which aims to identify biomarkers that…
GT-02287, an oral Parkinson’s disease therapy from Gain Therapeutics, showed promising results in a Phase 1b trial. Over three months of treatment, patients had lower levels of DOPA decarboxylase (DDC) in their cerebrospinal fluid — a biomarker linked to Parkinson’s activity. Motor function remained stable over five months of treatment.
Young adults with autism may show abnormalities in the activity of dopamine transporters — proteins that recycle dopamine after its release in the brain — that are commonly associated with Parkinson’s disease, according to a recent study. Using dopamine transporter imaging scans, or DaTscan, researchers identified abnormalities in…
GEN Pharmaceuticals has received ethical approval from an accredited medical research ethics committee in the Netherlands to conduct a small clinical trial testing SUL-238, its investigational medication for Parkinson’s disease. With this approval, the company will activate a clinical site in Groningen in the northern Netherlands with patient…
Vima Therapeutics is gearing up to launch a Phase 2 clinical trial this year to evaluate VIM0423, its potential first-in-class once-daily oral therapy for dystonia, or abnormal muscle tone, associated with Parkinson’s disease. Meanwhile, the first participant has been dosed in Stride Dystonia, a Phase 2…
Casma Therapeutics has been awarded $7.6 million from The Michael J. Fox Foundation (MJFF) to support the preclinical development of its CSM-101 therapy candidate for Parkinson’s disease. The funding includes a $2.1 million grant under the Targets to Therapies Initiative, which will be used for helping…
The integration of Kneu Health’s smartphone-based platform into Cedars-Sinai’s Parkinson’s care program enabled ongoing symptom monitoring and revealed the need for earlier intervention in 79% of encounters. According to the company, clinicians reported that the added insight helped care teams monitor treatment responses and inform more timely, personalized…
Recent Posts
- A sticky reminder about the dangers of losing your sense of smell
- New funding to support Serina’s SER-252 trial in advanced Parkinson’s
- Pirepemat shows promise in trial for reducing risk of falls in Parkinson’s
- When it comes to Parkinson’s, hope is not a plan, but urgent action is
- My uncle’s Parkinson’s progression changed some things, but not others